- Home
- Results news
- Amerise Biosciences
- Q2 FY27 results
Amerise Biosciences Q2 FY27 results: net loss widens to ₹0.06 crore
Amerise Biosciences Ltd reported a standalone net loss of ₹0.06 crore in Q2 FY27, against a net loss of ₹0.04 crore in Q2 FY26 and ₹0.08 crore in Q1 FY27. Revenue from operations was ₹0 crore for the quarter, while total expenses fell to ₹0.06 crore from ₹0.11 crore a year earlier. Basic EPS was ₹(0.01) for the quarter.
Key points
- Q2 FY27 standalone revenue from operations was ₹0 crore, unchanged from Q2 FY26 and Q1 FY27.
- Total expenses were ₹0.06 crore in Q2 FY27, down 45.5% from ₹0.11 crore in Q2 FY26.
- The company reported a net loss of ₹0.06 crore in Q2 FY27, compared with a net loss of ₹0.04 crore in Q2 FY26 and ₹0.08 crore in Q1 FY27.
- Basic EPS was ₹(0.01) for Q2 FY27, unchanged from Q1 FY27.
- Cash and cash equivalents were ₹0.02 crore as at 30 September 2026, against ₹0.02 crore as at 31 March 2026.
How did Amerise Biosciences perform in Q2 FY27?
Amerise Biosciences reported standalone revenue from operations of ₹0 crore in Q2 FY27, unchanged from Q2 FY26 and Q1 FY27. Total income was also ₹0 crore, against ₹0.07 crore in the year-ago quarter, while total expenses fell to ₹0.06 crore from ₹0.11 crore. EBITDA was reported at ₹0.06 crore, up ₹0.05 crore from Q2 FY26, but no EBITDA margin was given because revenue was nil.
On a standalone basis, the company reported a loss before tax of ₹0.06 crore in Q2 FY27, compared with a loss of ₹0.04 crore in Q2 FY26 and ₹0.08 crore in Q1 FY27. The net loss was ₹0.06 crore, with basic EPS of ₹(0.01). Tax expense was ₹0 crore and there was no exceptional item in either comparison quarter. The results were approved by the board on 30 October 2026 after review by the audit committee, and the statutory auditors carried out a limited review.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0 | 0 | 0 | ||
| Other income | 0 | 0 | 0.07 | ||
| Total expenses | 0.06 | 0.08 | 0.11 | −45.5% | −25.0% |
| EBITDA | −0.06 | −0.08 | −0.11 | ||
| Profit before tax | −0.06 | −0.08 | −0.04 | ||
| Tax | 0 | 0 | 0 | ||
| Net profit | −0.06 | −0.08 | −0.04 | ||
| EPS (₹) | −0.01 | −0.01 |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Amerise Biosciences' costs and profit?
The main change in the cost structure was other expenses, which fell to ₹0.05 crore in Q2 FY27 from ₹0.09 crore in Q2 FY26, a decline of ₹0.04 crore or 44.4%. Employee benefit expense fell to ₹0.01 crore from ₹0.02 crore, down ₹0.01 crore or 50.0%. Total expenses were lower by ₹0.05 crore, or 45.5%, at ₹0.06 crore against ₹0.11 crore in the year-ago quarter.
Other income was the main offset, falling to ₹0 crore in Q2 FY27 from ₹0.07 crore in Q2 FY26, a decline of ₹0.07 crore. Cost of materials consumed, finance costs and depreciation were each unchanged at ₹0 crore. Tax expense was unchanged at ₹0 crore, and there was no exceptional item in the quarter. Against the previous quarter, other expenses fell ₹0.02 crore or 28.6%, while employee cost was unchanged and other income stayed at ₹0 crore.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0 | 0 | 0 | |
| Employee cost | 0.01 | 0.02 | −0.01 | −50.0% |
| Finance costs | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | |
| Other expenses | 0.05 | 0.09 | −0.04 | −44.4% |
| Total expenses | 0.06 | 0.11 | −0.05 | −45.5% |
| Other income | 0 | 0.07 | −0.07 | |
| Tax | 0 | 0 | 0 |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For the first half of FY27, revenue from operations was ₹0 crore, unchanged from H1 FY26, and total income was ₹0 crore against ₹0.13 crore. Total expenses fell to ₹0.06 crore in H1 FY27 from ₹0.11 crore in H1 FY26, while employee benefit expense was ₹0.01 crore against ₹0.02 crore and other expenses were ₹0.05 crore against ₹0.09 crore.
The loss before tax widened to ₹0.14 crore in H1 FY27 from ₹0.05 crore in H1 FY26, an increase of ₹0.09 crore. Net loss was also ₹0.14 crore against ₹0.05 crore, and basic EPS was ₹(0.02) for the half year compared with ₹(0.01) in H1 FY26. Other income was ₹0 crore in H1 FY27 against ₹0.13 crore in H1 FY26, and there was no exceptional item in either period.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 0 | 0 | |
| Profit before tax | −0.14 | −0.05 | |
| Net profit | −0.14 | −0.05 | |
| EPS (₹) | −0.02 | −0.01 |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
For the first half of FY27, net cash flow from operating activities was ₹(0.64) crore, against ₹(0.07) crore in H1 FY26. Net cash flow from investing activities was ₹0.04 crore against ₹0.07 crore, and net cash flow from financing activities was ₹0.03 crore against ₹0 crore. Capital expenditure was ₹0 crore in both periods.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 6.81 | 7.42 |
| Total equity | 5.26 | 5.40 |
| Borrowings | 0.03 | 0 |
| Cash and equivalents | 0.02 | 0.02 |
| Inventories | 0 | 0 |
| Trade receivables | 0 | 0 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −0.64 | −0.07 |
| Cash from investing | 0.04 | 0.07 |
| Cash from financing | 0.03 | 0 |
| Capital expenditure | 0 | 0 |
Source: Company's results filing (XBRL).
How has Amerise Biosciences done over the last 8 quarters?
Revenue from operations over the last eight quarters peaked at ₹0.19 crore in Q4 FY25 and was ₹0.08 crore in Q4 FY26, while it stood at ₹0.06 crore in Q1 FY26 and ₹0 crore in Q2 FY27. The most recent quarters show no revenue recorded in the sequential pattern.
Profit has alternated between profit and loss. The company reported a net profit of ₹0.11 crore in Q4 FY25 and ₹0.06 crore in Q4 FY26, against net losses of ₹0.04 crore in Q2 FY26, ₹0.08 crore in Q1 FY27 and ₹0.06 crore in Q2 FY27. The EBITDA margin peaked at 77.4% in Q4 FY26, after 56.3% in Q4 FY25, and was negative 12.7% in Q1 FY26.
What else did the company announce?
Around the result, Amerise Biosciences filed with BSE on 23 October 2026 to inform the exchange that the board would meet on 30 October 2026 to approve the un-audited results for the quarter and half year ended 30 September 2026. The board meeting began at 03:45 PM and concluded at 04:15 PM on 30 October 2026.
A same-day disclosure from Snehjeev Ventures Private Limited stated that it and persons acting in concert acquired 8603076 equity shares, representing 13.02% of the total capital of Amerise Biosciences, as on 28 October 2026. The filing said the shares were acquired in the open market, taking the holding from 12.99% to 13.02%.
How did Amerise Biosciences shares react?
After the filing, the Amerise Biosciences share price was unchanged at 5 and 15 minutes, then fell 2.4% by 30 minutes. On the reaction day, from the previous close of ₹0.82, the stock rose 2.4%. By the next day's close it was up 4.9% from its pre-results close. The stock price was 0.82 at the time of the filing.
| After the filing | Stock | Plastic Products - Industrial median |
|---|---|---|
| 5 minutes | +0.0% | |
| 15 minutes | +0.0% | |
| 30 minutes | −2.4% | |
| Reaction day | +2.4% | +0.6% |
| Next day | +4.9% | +0.9% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 3 August 2026 | −4.2% |
| 5 May 2026 | +4.2% |
| 2 February 2026 | +4.5% |
| 5 November 2025 | +1.6% |
| 24 July 2025 | −1.3% |
| 19 May 2025 | +3.7% |
| 22 October 2024 | +1.1% |
| 6 August 2024 | +1.5% |
Source: MarketPing price-reaction measurement.
How did other Plastic Products - Industrial companies do?
Seventeen Plastic Products - Industrial companies were compared for revenue growth this quarter, with a median revenue growth of 22.1%. Of the 20 peers compared for profit, 12 reported higher profit. Peer revenue and profit comparisons were as at 4 November 2026.
| Amerise Biosciences revenue growth (YoY) | not comparable |
|---|---|
| Median of 17 other Plastic Products - Industrial companies | +22.1% |
| Companies whose net profit rose | 12 of 20 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Amerise Biosciences' revenue in Q2 FY27?
Revenue from operations was ₹0 crore, against ₹0 crore in Q2 FY26 (standalone).
Did Amerise Biosciences make a profit in Q2 FY27?
No. It reported a net loss of ₹0.06 crore, against a net loss of ₹0.04 crore in Q2 FY26.
What was Amerise Biosciences' EPS in Q2 FY27?
Basic loss per share was ₹0.01.
How did Amerise Biosciences shares react to the Q2 FY27 results?
On the reaction day the stock moved +2.4% from the previous close; the median Plastic Products - Industrial stock moved +0.6%.
When did Amerise Biosciences announce its Q2 FY27 results?
On 30 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting. (BSE, 23 October 2026) · PDF
- Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations") (BSE, 30 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.